What RevMed’s pancreatic cancer drug meant for one patient - Top-Institutions - MDSpire

What RevMed’s pancreatic cancer drug meant for one patient

  • By

  • Elaine Chen

  • Adam Feuerstein

  • Allison DeAngelis

  • June 4, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of California, Los Angeles (UCLA) Health
    University of California, Los Angeles (UCLA) Health

    Los Angeles, CA

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Winship Cancer Institute
    Winship Cancer Institute

    Atlanta, GA

    Key Differentiators

    • Oncology

  • #4

    Medical College of Wisconsin
    Medical College of Wisconsin

    Milwaukee, WI

    Key Differentiators

    • Oncology

  • #5

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

Original Source(s)

What RevMed’s pancreatic cancer drug meant for one patient

  • by Elaine Chen, Adam Feuerstein, Allison DeAngelis

  • June 4, 2026

Related Content

Incidence and Survival of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in the Contemporary Era

The intratumoral microbiome: a review of the tumor microenvironment’s fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response

A case report of splenic malignancy originating from the liver